Analystreport

UroGen Pharma Ltd. (NASDAQ: URGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $10.00 to $11.00. They now have a "neutral" rating o

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com